Status message

Not the entire site translated, but only to "Journal"

Drug Therapy for Patients with Mental Disorders Who Have a Coronavirus Infection (COVID-19)

S.N. Mosolov, D I. Malin, E E. Tsukarzi, E.G. Kostyukova

FSBI “National Medical Research Center for Psychiatry and Addiction named after V.P. Serbian” Ministry of Health of Russian Federation, Moscow, Russia

Summary
The article describes the features of drug therapy for patients with mental disorders who have a coronavirus infection (COVID-19). These questions are extremely relevant for practicing Russian psychiatrists at the moment, since according to data from China and Italy during the epidemic, psychiatric patients were more vulnerable to its spread than the healthy population, and had a higher risk of severe disease and complications. The article discusses the reasons for the greater vulnerability of this group of patients to the spread of infection. Based on the literature analysis, data on possible drug interactions between psychotropic drugs and drugs used for the treatment of patients with coronavirus infection are presented. Special attention is paid to adverse reactions that may occur in patients with hyperthermia, respiratory and heart failure when using psychotropic drugs, as well as tactics for relieving psychomotor agitation. Recommendations are given for the treatment of patients with mental pathology and COVID-19, include correction of dosages of psychotropic drugs, the use of drugs with minimal side effects, consideration of possible adverse drug interactions, careful monitoring of the somatic state of patients.

Contact: profmosolov@mail.ru
https://orcid.org/0000000257493964

CITATION: Mosolov S.N., Malin D.I., Tsukarzi E.E., Kostyukova E.G. Drug Therapy for Patients with Mental Disorders Who Have a Coronavirus Infection (COVID-19) // Sovrem. ter. psih. rasstrojstv. – 2020. – No. 2. – DOI: 10.21265/PSYPH.2020.18.69.001

References: 

1.    China Newsweek. Collective infections of coronavirus among 50 patients and 30 health workers in one psychiatric hospital in Wuhan // Shanghai Obs. – 2020. – Available at:  https://www.jfdaily.com/news/detail?id=208584 (accessed Feb 17, 2020; in Chinese).
2.    Fagiolini A., Cuomo A., Frank E. COVID-19 diary from a psychiatry department in Italy // J Clin Psychiatry. – 2020. – No. 81. – DOI: 10.4088/JCP.20com13357
3.    Seminog O.O., Goldacre M.J. Risk of pneumonia and pneumococcal disease in people with severe mental illness: English record linkage studies // Thorax. – 2013. – Vol. 68. – P. 171–176.
4.    Sartorius N. Comorbidity of mental and physical diseases: a main challenge for medicine of the 21st century // Shanghai Arch Psychiatry. – 2013. – Vol. 25. – P. 68–69.
5.    Psikhiatriya: natsional'noe rukovodstvo. Kratkoe izdanie / pod red. T.B. Dmitrievoi, V.N. Krasnova, N.G. Neznanova, V.Ya. Semke, A.S. Tiganova, Yu.A. Aleksandrovskogo. – M.: GEOTAR-Media, 2012. – 624 s.
6.    Biologicheskie metody terapii psikhicheskikh rasstroistv (dokazatel'naya meditsina – klinicheskoi praktike) / pod red. S.N. Mosolova. – M.: Sotsial'no-politicheskaya mysl', 2012. – 1073 s.
7.    Mosolov S.N. Osnovy psikhofarmakoterapii. – M.: Vostok, 1996. – 286 s.
8.    Mosolov S.N. Klinicheskoe primenenie sovremennykh antidepressantov. – SPb.: Meditsinskoe informatsionnoe agentstvo, 1995. – 568 s.
9.    Raiskii V.A. Psikhotropnye sredstva v klinike vnutrennikh boleznei. – M.: Meditsina, 1988. – 265 s.
10.    Neznanov N.G., Mosolov S.N., Ivanov M.V. Psikhofarmakoterapiya // Psikhiatriya. Natsional'noe rukovodstvo. M.:  (2018), razdel VIII, glava 29, – s. 820–893
11.    Malin D.I. Pobochnoe deistvie psikhotropnykh sredstv. – M.: Vuzovskaya kniga, 2000. – 207 s. 
12.    Paul K., Walker R. Anticholinergic medications and risk of community-acquired pneumonia in elderly adults: a population-based older adults: a populations- based case-contral study // J Am Geriatr Soc. – 2015.–Vol. 63. – P. 476–485.
13.    Dublin S., Walker RL, Jackson ML, et al. Use of opioids or benzodiazepines and risk of pneumonia in older adults: a population-based case-control study // J Am Geriatr Soc. – 2011. – Vol. 59. – P. 1899–1907.
14.    Psikhiatriya: spravochnik prakticheskogo vracha / pod red. A.G. Gofmana. – 2-e izd., pererab. – M.:  MEDPress-inform, 2010. – 608 s. 
15.    Stein D.J. Pharmacotherapy of adjustment disorder: a review // World J Biol Psychiatry. – 2018. – Vol. 19, Suppl. 1. – P. 46–52.
16.    U.S. Food and Drug Administration. 19 décembre 2019. – Available at: https://www.fda.gov/news-events/fda-brief/fda-brief-fda-requires-new-war... (accessed March 24, 2020).
17.    Chan H.Y., Lai C.L., Lin Y.C. et al. Is Antipsychotic Treatment Associated With Risk of Pneumonia in People With Serious Mental Illness? The Roles of Severity of Psychiatric Symptoms and Global Functioning // J Clin Psychopharmacol. – 2019, Sep/Oct. – Vol. 39 (5). – P. 434–440.
18.    Mosolov S.N., Tsukarzi E.E. Psikhofarmakoterapiya shizofrenii // Psikhiatriya: natsional'noe rukovodstvo / pod red. N.G. Neznanova, Yu.A. Aleksandrovskogo. – M.: GEOTAR-Media, 2018. – S. 299–333.
19.    Tsukarzi E.E. Neotlozhnaya pomoshch' pri agressivnom povedenii. Chast' II. Vedenie patsientov // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2013. – № 2. – C. 31–34.
20.    Gaynes B.N., Brown C., Lux L.J. et al. Strategies to De-escalate Aggressive Behavior in Psychiatric Patients. AHRQ Comparative Effectiveness Reviews. – Report no. 16-EHC032-EF. – Rockville, MD: Agency for Healthcare Research and Qualit, 2016.
21.    Putkonen A., Kuivalainen S., Louheranta O. et al. Cluster-randomized controlled trial of reducing seclusion and restraint in secured care of men with schizophrenia // Psychiatr Serv. – 2013. Vol. 64. – P. 850–855. 
22.    Mantovani C., Labate C.M., Sponholze A.J. et al. Are low doses of antipsychotics effective in the management of psychomotor agitation? A randomized, rated-blind trial of 4 intramuscular interventions // J Clin Psychopharmacol. – 2013. – Vol. 33. – P. 306–312.
23.    Federal'noe rukovodstvo po ispol'zovaniyu lekarstvennykh sredstv (formulyarnaya sistema) / pod red. A.G. Chuchalina, Yu.B. Belousova, V.V. Yasnetsova. – 7-e izd., pererab. i dop. – M.: Ekho, 2006. – 957 c.
24.    Federal'noe rukovodstvo po ispol'zovaniyu lekarstvennykh sredstv (formulyarnaya sistema) / pod red. A.G. Chuchalina. – Vyp. IV. – M.: Ekho, 2003. – 956 s.
25.    Pasin L., Landoni G., Nardelli P., et al. Dexmedetomidine reduces the risk of delirium, agitation and confusion in critically Ill patients: A meta-analysis of randomized controlled trials // J Cardiothorac Vasc Anesth. – 2014. – Vol. 28. – P. 1459–1466.
26.    Mosolov S.N., Malin D.I., Ryvkin P.V., Sychev D.A. Lekarstvennye vzaimodeistviya preparatov, primenyaemykh v psikhiatricheskoi praktike // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2019. – № S1 (dopolnitel'nyi tematicheskii vypusk). – S. 2–35.
27.    Wynn G.H., Oesterheld I.R., Cozza K.L., Armstrong S.C. Clinical Manual of Drug Interaction. Principles for medical practice, APP. – Washington DC, 2009. – 594 p.
28.    Goodlet K.J., Zmarlicka M.T., Peckham A. Drug-drug interactions and clinical considerations with co-administration of antiretrovirals and psychotropic drugs // SNS Spectrums. – 2018. – P. 1–26. – DOI: 10.1017/S109285291800113X
29.    Psikhofarmakologicheskie i protivoepilepticheskie sredstva, razreshennye k primeneniyu v Rossii / pod red. S.N. Mosolova. – M.: OOO «Izdatel'stvo “BINOM. Laboratoriya znanii”», 2004. – 301 s.
30.    Federal'noe rukovodstvo po ispol'zovaniyu lekarstvennykh sredstv (formulyarnaya sistema) / pod red. A.G. Chuchalina. – Vyp. XIII. – M.: Ekho, 2012. – 984 s.
31.    Federal'noe rukovodstvo po ispol'zovaniyu lekarstvennykh sredstv (formulyarnaya sistema) / pod red. A.G. Chuchalina. – 12-e izd., pererab. i dop. – M.: Chelovek i lekarstvo, 2011. – 956 s.
32.    Vidal. Spravochnik lekarstvennykh sredstv. – URL: https://www.vidal.ru/ (data obrashcheniya 30.03.2020).
33.    DeSilva K.E., le Flore D.B., Marston B.J. et al. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine // AIDS. – 2001. – Vol. 15 (10). – P. 1281–1285.
34.    Surgers L., Lacombe K. Hepatoxicity of new antiretrovirals: a systematic review // Clin Res Hepatol Gastroenterol. – 2013. – Vol. 37 (2). – P. 126–133.
35.    Badalov N., Baradarian R., Iswara K. et al. Drug-induced acute pancreatitis: An evidence-based review // Clin Gastroenterol Hepatol. – 2007. – Vol. 5 (6). – P. 648–661.
36.    Depakote® [package insert]. – North Chicago, IL: AbbVie Inc., October 2017.
37.    DiCenzo R., Peterson D., Cruttenden K. et al. Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults // Antimicrob Agents Chemother. – 2004. – Vol. 48 (11). – P. 4328–4331.
38.    Sheehan N.L., Brouillette M.J., Delisle M.S. et al. Possible interaction between lopinavir/ritonavir and valproic acid exacerbates bipolar disorder // Ann Pharmacother. – 2006. – Vol. 40 (1). – P. 147–150.
39.    Van der Lee M.J., Dawood L., ter Hofstede H.J. et al. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects // Clin Pharmacol Ther. – 2006. – Vol. 80 (2). – P. 159–168.
40.    Burger D.M., Huisman A., Van Ewijk N. et al. The effect of atazanavir and atazanavir/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenotypic probe // Clin Pharmacol Ther. – 2008. – Vol. 84 (6). – P. 698–703.
41.    Tegretol® [package insert]. – East Honover, N.J.: Novartis Pharmaceuticals Corporation, April 2017.
42.    Remdesivir. – Available at: https://www.drugbank.ca/drugs/DB14761 (accessed March 24, 2020).
43.    FDA / U.S. Food and Drug Administration. 29. 07. 2013. Drug Safety Communication: FDA approves label changes for antimalarial drug mefloquine hydrochloride due to risk of serious psychiatric and nerve side effects. – Available at: https://www.fda.gov/media/86285 (accessed March 30, 2020).
44.    Federal'noe rukovodstvo po ispol'zovaniyu lekarstvennykh sredstv (formulyarnaya sistema) / pod red. A.G. Chuchalina, Yu.B. Belousova, V.V. Yasnetsova. – 8-e izd., pererab. i dop. – M.: Ekho, 2007. – 1008 s.
45.    Sartorius N., Barrett B., Bauman P. i dr. Terapiya antidepressantami i drugie metody lecheniya depressivnykh rasstroistv: doklad Rabochei gruppy CINP na osnove obzora dokazatel'nykh dannykh / per. s angl.; Rossiiskoe obshchestvo psikhiatrov. – M, 2008. – 215 c.